HopeStage
Back to all studies
CompletedNCT02249299

Cannabinoids and ADHD Symptoms in Adults

About this titleRead the official source — NCT02249299
Medication studyAges 18–55United Kingdom
The study in practice

Understand this study

Who was this study for?

This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
LondonSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 2014
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
King's College London
Sponsor type
University
Study type
Drug
Intervention type
Drug
Locations
United Kingdom
Age range
From 18 Years to 55 Years
Official registry ID
NCT02249299
Official title
Show the full official title

The Effects of Sativex on Neurocognitive and Behavioural Function in Adults With Attention-deficit/Hyperactivity Disorder; The EMA-C Study (Experimental Medicine in ADHD - Cannabinoids)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is King's College London, a university.

Did this study involve medication?

Yes. The study involved medication, including Sativex Oromucosal Spray and Placebo.

Who was this study for?

This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies